GSK Price Prediction Next Week
Analysis and Insights
Based on the analysis of news sentiment and technical indicators, here is the prediction for GSK's stock price for the next trading week:
News Sentiment Analysis:
- The rescheduled CDC vaccine meeting on April 15-16, where GSK is expected to participate, could positively impact investor sentiment as it highlights GSK's role in the vaccine industry.
- Concerns over potential cuts to HIV prevention funding may weigh on GSK's stock due to its stake in ViiV Healthcare, a major HIV drugmaker.
Technical Indicators:
- RSI (14): 57.04, indicating a neutral position, not overbought or oversold.
- MACD: The MACD line is above the signal line, suggesting a bullish signal.
- Fibonacci Levels: Resistance at 40.51 and support at 38.96, with a pivot point at 39.74.
Price Prediction:
- Predicted Price: 40.5
- Recommendation: Buy
GSK Similar Chart Price Prediction
The price of GSK is predicted to go up 9.89%, based on the high correlation periods with RMAX. The similarity of these two price pattern on the periods is 96.82%.
GSK
RMAX
Up: 9.89%Similarity: 96.82%
GSK Revenue Forecast
GSK EPS Forecast
GSK FAQs
What is GSK revenue forecast for next quarter？
What is GSK eps forecast for next quarter？
GSK VS S&P500
GSK's next-generation respiratory drugs and HIV drugs look poised for strong growth over the next three years.
GSK faces relatively minor near-term patent losses, setting up steady growth over the next three years.
GSK's well-positioned RSV vaccine Arexvy should support strong long-term growth based on excellent efficacy and limited competition.
GSK Analyst's Forecast
Peter Welford
Jefferies
Strong Buy → Hold
2024-11-12
Price Target
n/a
Downside
0%
Jefferies analyst Peter Welford downgraded GSK to Hold from Buy with a price target of $39.50, down from $53. The firm finds it "frustrating" that despite the favorable Zantac settlement, robust performance of GSK's Specialty unit, and pipeline successes, the shares "continue to languish." While GSK's fundamental value remains compelling, overhangs for the company's Arexvy and Shingrix vaccines, "more subdued" 2025 growth, and few near-term catalysts to "rebuild belief" suggests the stock's value disconnect may persist, the analyst tells investors in a research note.
Seamus Fernandez
Guggenheim
Strong Buy → Hold
2024-10-31
Price Target
n/a
Downside
0%
